uzspbgmuУчёные записки Первого Санкт-Петербургского государственного медицинского университета имени академика И. П. ПавловаThe Scientific Notes of the Pavlov University1607-41812541-8807Academician I.P. Pavlov First St. Petersburg State Medical University10.24884/1607-4181-2023-30-3-16-21uzspbgmu-1048Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESФункция липопротеинов высокой плотности при различных патологических состоянияхHigh-densitylipoprotein function in various pathological conditionshttps://orcid.org/0000-0002-0581-7285СмирноваН. Н.SmirnovaN. N.

Смирнова Наталия Николаевна, доктор медицинских наук, профессор, зав. кафедрой педиатрии

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Smirnova Natalia N., Dr. of Sci. (Med), Professor, Head of the Department of Pediatrics

6-8, L’va Tolstogo str., Saint Petersburg, 197022

nephro-uro-kids@mail.ruhttps://orcid.org/0000-0003-2054-3419КуприенкоН. Б.KuprienkoN. В.

Куприенко Наталья Борисовна, кандидат медицинских наук, доцент кафедры педиатрии

197022, Санкт-Петербург, ул. Льва Толстого, д. 6-8

Kuprienko Natalia B., Cand. of Sci. (Med), Associate Professor of the Department of Pediatrics

6-8, L’va Tolstogo str., Saint Petersburg, 197022

https://orcid.org/0000-0003-3046-372XУразгильдееваС. А.UrazgildeevaS. А.

Уразгильдеева Сорейя Асафовна, доктор медицинских наук, ведущий научный сотрудник отдела атеросклероза научно-клинического и  образовательного центра «Кардиология»

Санкт-Петербург

Urazgildeeva Soreiia A., Cand. of Sci. (Med), Leading Research Fellow of Atherosclerosis Department, Scientific, Clinical and Educational Center«Cardiology»

Saint Petersburg

Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияPavlov UniversityRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный университет»РоссияSaint-Petersburg UniversityRussian Federation2023020420243031621Copyright © Смирнова Н.Н., Куприенко Н.Б., Уразгильдеева С.А., 20242024Смирнова Н.Н., Куприенко Н.Б., Уразгильдеева С.А.Smirnova N.N., Kuprienko N.В., Urazgildeeva S.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sci-notes.ru/jour/article/view/1048

В обзоре рассмотрены изменения структуры и функции липопротеинов высокой плотности (ЛВП), играющие важную роль в патогенезе ряда хронических заболеваний, так или иначе стимулирующих развитие атеросклероза. Доказано, что функция ЛВП нарушается при ряде генетических и приобретенных заболеваний, ведущих к дислипидемии и связанных с повышенным сердечно-сосудистым риском, таких как семейная гиперхолестеринемия, ожирение, метаболический синдром, хроническая болезнь почек, сахарный диабет, воспалительные и аутоиммунные заболевания.

The review considers changes in the structure and function of high-density lipoproteins (HDL), which play an important role in the pathogenesis of a number of chronic diseases that somehow stimulate the development of atherosclerosis. HDL function has been shown to be impaired in a number of genetic and acquired diseases leading to dyslipidemia and associated with increased cardiovascular risk such as familial hypercholesterolemia, obesity, metabolic syndrome, chronic kidney disease, diabetes mellitus, inflammatory and autoimmune diseases.

липопротеины высокой плотностиатеросклерозсемейная гиперхолестеринемияожирениехроническая болезнь почексахарный диабетhigh-density lipoproteinsatherosclerosisfamilial hypercholesterinemiaobesitychronic kidney diseasediabetes mellitusReferencesSoria-Florido M. T., Schröder H., Grau M. et al. High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis // Atherosclerosis. – 2020. – Vol. 302. – P. 36–42. DOI: 10.1016/j.atherosclerosis.2020.04.015.Soria-Florido M.T., Schröder H., Grau M. et al. High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis // Atherosclerosis. 2020;302:36–42. DOI: 10.1016/j.atherosclerosis.2020.04.015.Khera A. V., Cuchel M., de la Llera-Moya M. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis // N. Engl. J. Med. – 2011. – Vol. 364. – P. 127–135. DOI: 10.1056/NEJMoa1001689.Khera A. V., Cuchel M., de la Llera-Moya M. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis // N. Engl. J. Med. 2011;364:127–135. DOI: 10.1056/NEJMoa1001689.Перова Н. В. Атеромаркеры липопротеинов высокой плотности. Часть I. Липопротеины высокой плотности: структура, состав, физико-химические и физиологические антиатерогенные свойства, их механизмы и маркеры (обзор литературы) // Профилактическая медицина. – 2017. – Т. 20, № 3. – С. 47–54.Perova N. V. Atheromarkers of high-density lipoproteins. Part 1. High-density lipoproteins: Structure, composition, physicochemical and physiological antiatherogenic properties, their mechanisms and markers (a review of literature) // Profilakticheskaya Meditsina. 2017;20(3):47–54. (In Russ.). DOI: 10.17116/profmed201720347-54.Agarwala A. P., Rodrigues A., Risman M. et al. High-Density Lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease // Arterioscler. Thromb. Vasc. Biol. – 2015. – Vol. 35. – P. 1515–1519. DOI: 10.1161/ATVBAHA.115.305504.Agarwala A. P., Rodrigues A., Risman M. et al. HighDensity Lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease // Arterioscler. Thromb. Vasc. Biol. 2015;35:1515–1519. DOI: 10.1161/ATVBAHA.115.305504.Thakkar H., Vincent V., Roy A et al. HDL functions and their interaction in patients with ST elevation myocardial infarction: A case control study // Lipids Health Dis. – 2020. – Vol. 19. – P. 75. DOI: 10.1186/s12944-020-01260-4.Thakkar H., Vincent V., Roy A et al. HDL functions and their interaction in patients with ST elevation myocardial infarction: A case control study // Lipids Health Dis. 2020;19:75. DOI: 10.1186/s12944-020-01260-4.Agarwala A. P., Rodrigues A., Risman M. et al. HighDensity Lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease // Arterioscler. Thromb. Vasc. Biol. – 2015. – Vol. 35. – P. 1515–1519. DOI: 10.1161/ATVBAHA.115.305504.Agarwala A. P., Rodrigues A., Risman M. et al. High-Density Lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease // Arterioscler. Thromb. Vasc. Biol. 2015;35:1515–1519. DOI: 10.1161/ATVBAHA.115.305504.Soria-Florido M. T., Castañer O., Lassale C. et al. Dysfunctional high-density lipoproteins are associated with a greater incidence of acute coronary syndrome in a population at high cardiovascular risk: a nested case-control study // Circulation. – 2020. – Vol. 141, № 6. – P. 444–453. DOI: 10.1161/CIRCULATIONAHA.119.041658.Soria-Florido M. T., Castañer O., Lassale C. et al. Dysfunctional high-density lipoproteins are associated with a greater incidence of acute coronary syndrome in a population at high cardiovascular risk: a nested case-control study // Circulation. 2020:444–453. DOI: 10.1161/CIRCULATIONAHA.119.041658.Christensen J. J., Narverud I., Ruuth M. et al. Children with familial hypercholesterolemia display changes in LDL and HDL function: A cross-sectional study // J Intern Med. – 2021. – Vol. 290, № 5. – P. 1083–1097. DOI: 10.1111/joim.13383.Christensen J. J., Narverud I., Ruuth M. et al. Children with familial hypercholesterolemia display changes in LDL and HDL function: A cross-sectional study // J Intern Med. 2021;290(5):1083–1097. DOI: 10.1111/joim.13383.Ottestad I. O., Halvorsen B., Balstad T. R. et al. Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux // J. Nutr. – 2006. – Vol. 136. – P. 877–881. DOI: 10.1093/jn/136.4.877.Ottestad I. O., Halvorsen B., Balstad T. R. et al. Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux // J. Nutr. 2006;136:877–881. DOI: 10.1093/jn/136.4.877.Hussein H., Saheb S., Couturier M. et al. Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis // J Clin Lipidol. – 2016. – Vol. 10, № 1. – P. 124–33. DOI: 10.1016/j.jacl.2015.10.006.Hussein H., Saheb S., Couturier M. et al. Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis // J Clin Lipidol. 2016;10(1):124–33. DOI: 10.1016/j.jacl.2015.10.006.Talbot C. P. J., Plat J., Joris P. J. et al. HDL cholesterol efflux capacity and cholesteryl ester transfer are associated with body mass, but are not changed by diet-induced weight loss: A randomized trial in abdominally obese men // Atherosclerosis. – 2018. – Vol. 274. – P. 23–28. DOI: 10.1016/j.atherosclerosis.2018.04.029.12.Talbot C. P.J., Plat J., Joris P.J. et al. HDL cholesterol efflux capacity and cholesteryl ester transfer are associated with body mass, but are not changed by diet-induced weight loss: A randomized trial in abdominally obese men // Atherosclerosis. 2018;274:23–28. DOI: 10.1016/j.atherosclerosis.2018.04.029.12.Vazquez E., Sethi A. A., Freeman L. et al. High-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese women // Am. J. Cardiol. – 2012. – Vol. 109. – P. 527–532. DOI: 10.1016/j.amjcard. 2011.10.008.Vazquez E., Sethi A.A., Freeman L. et al. High-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese women // Am. J. Cardiol. 2012;109:527–532. DOI: 10.1016/j.amjcard.2011.10.008.Marsche G., Zelzer S., Meinitzer A. et al. Adiponectin predicts high-density lipoprotein cholesterol efflux capacity in adults irrespective of body mass index and fat distribution // J. Clin. Endocrinol. Metab. – 2017. – Vol. 102. – P. 4117–4123. DOI: 10.1210/jc.2017-00933.Marsche G., Zelzer S., Meinitzer A. et al. Adiponectin predicts high-density lipoprotein cholesterol efflux capacity in adults irrespective of body mass index and fat distribution // J. Clin. Endocrinol. Metab. 2017;102:4117–4123. DOI: 10.1210/jc.2017-00933.Успенский Ю. П., Петренко Ю. В., Гулунов З. Х. и др. Метаболический синдром. Учебное пособие. – СПб., 2017. – 60 с.Uspensky Y. P., Petrenko Y. V., Gulunov Z. H. et al. Metabolic syndrome. Study guide. St. Petersburg, 2017:60. 15. Stadler J. T., Marsche G. Obesity-related changes in high-density lipoprotein metabolism and function // Int. J. Mol. Sci. 2020;21:8985. DOI: 10.3390/ijms21238985.Stadler J. T., Marsche G. Obesity-related changes in high-density lipoprotein metabolism and function // Int. J. Mol. Sci. – 2020. – Vol. 21. – P. 8985. DOI: 10.3390/ijms21238985.Wang H. H., Lee D. K., Liu M. et al. Novel insights into the pathogenesis and management of the metabolic syndrome // Pediatr. Gastroenterol. Hepatol. Nutr. 2020;23:189– 230. DOI: 10.5223/pghn.2020.23.3.189.Wang H. H., Lee D. K., Liu M. et al. Novel insights into the pathogenesis and management of the metabolic syndrome // Pediatr. Gastroenterol. Hepatol. Nutr. – 2020. – Vol. 23. – P. 189–230. DOI: 10.5223/pghn.2020.23.3.189.Gall J., Frisdal E., Bittar R. et al. Association of cholesterol efflux capacity with clinical features of metabolic syndrome: Relevance to atherosclerosis // J. Am. Heart Assoc. 2016;5:1–13. DOI: 10.1161/JAHA.116.004808.1007/s00592-015-0824-y.Gall J., Frisdal E., Bittar R. et al. Association of cholesterol efflux capacity with clinical features of metabolic syndrome: Relevance to atherosclerosis // J. Am. Heart Assoc. – 2016. – Vol. 5. – P. 1–13. DOI: 10.1161/JAHA.116.004808.1007/s00592-015-0824-y.Nur Zati Iwani A. K., Jalaludin M. Y., Yahya A. et al. TG: HDL-C ratio as insulin resistance marker for metabolic syndrome in children with obesity // Front Endocrinol (Lausanne). 2022;13:852290. DOI: 10.3389/fendo.2022.852290.Nur Zati Iwani A. K., Jalaludin M. Y., Yahya A. et al. TG: HDL-C ratio as insulin resistance marker for metabolic syndrome in children with obesity // Front Endocrinol (Lausanne). – 2022. – Vol. 13. – P. 852290. DOI: 10.3389/fendo.2022.852290.Podkowińska A., Formanowicz D. Chronic kidney disease as oxidative stress-and inflammatory-mediated cardiovascular disease // Antioxidants. 2020;9:752. DOI: 10.3390/antiox9080752.Podkowińska A., Formanowicz D. Chronic kidney disease as oxidative stress-and inflammatory-mediated cardiovascular disease // Antioxidants. – 2020. – Vol. 9. – P. 752. DOI: 10.3390/antiox9080752.Rysz J., Gluba-Brzózka A., Rysz-Górzyńska M., Franczyk B. The role and function of HDL in patients with chronic kidney disease and the risk of cardiovascular disease // Int. J. Mol. Sci. 2020;21:601. DOI: 10.3390/ijms21020601.Rysz J., Gluba-Brzózka A., Rysz-Górzyńska M., Franczyk B. The role and function of HDL in patients with chronic kidney disease and the risk of cardiovascular disease // Int. J. Mol. Sci. – 2020. – Vol. 21. – P. 601. DOI: 10.3390/ijms21020601.Meier S. M., Wultsch A., Hollaus M. et al. Effect of chronic kidney disease on macrophage cholesterol efflux // Life Sci. 2015;136:1–6. DOI: 10.1016/j.lfs.2015.06.005.Meier S. M., Wultsch A., Hollaus M. et al. Effect of chronic kidney disease on macrophage cholesterol efflux // Life Sci. – 2015. – Vol. 136. – P. 1–6. DOI: 10.1016/j.lfs.2015.06.005.Gipson G. T., Carbone S., Wang J. et al. Impaired delivery of cholesterol effluxed from macrophages to hepatocytes by serum from CKD patients may underlie increasedcardiovascular disease risk // Kidney Int. Reports. 2020; 5:199–210. DOI: 10.1016/j.ekir.2019.11.003.Gipson G. T., Carbone S., Wang J. et al. Impaired delivery of cholesterol effluxed from macrophages to hepatocytes by serum from CKD patients may underlie increased cardiovascular disease risk // Kidney Int. Reports. – 2020. – Vol. 5. – P. 199–210. DOI: 10.1016/j.ekir.2019.11.003.Lightbody R. J., Taylor J. M. W., Dempsie Y., Graham A. MicroRNA sequences modulating inflammation and lipid accumulation in macrophage “foam” cells: Implications for atherosclerosis // World J. Cardiol. 2020;12:303–333. DOI: 10.4330/wjc.v12.i7.303.Lightbody R. J., Taylor J. M. W., Dempsie Y., Graham A. MicroRNA sequences modulating inflammation and lipid accumulation in macrophage “foam” cells: Implications for atherosclerosis // World J. Cardiol. – 2020. – Vol. 12. – P. 303–333. DOI: 10.4330/wjc.v12.i7.303.Nazir S., Jankowski V., Bender G. et al. Interaction between high-density lipoproteins and inflammation: Function matters more than concentration! // Adv. Drug Deliv. Rev. 2020;159:94–119. DOI: 10.1016/j.addr.2020.10.006.Nazir S., Jankowski V., Bender G. et al. Interaction between high-density lipoproteins and inflammation: Function matters more than concentration! // Adv. Drug Deliv. Rev. – 2020. – Vol. 159. – P. 94–119. DOI: 10.1016/j.addr.2020.10.006.Tanaka S., Couret D., Tran-Dinh A. et al. High-density lipoproteins during sepsis: From bench to bedside // Crit. Care. 2020;24:1–11. DOI: 10.1186/s13054-020-02860-3.Tanaka S., Couret D., Tran-Dinh A. et al. High-density lipoproteins during sepsis: From bench to bedside // Crit. Care. – 2020. – Vol. 24. – P. 1–11. DOI: 10.1186/s13054-020-02860-3.Sharma N. K., Tashima A. K., Brunialti M. K. C. et al. Proteomic study revealed cellular assembly and lipid metabolism dysregulation in sepsis secondary to community-acquired pneumonia // Sci. Rep. 2017;7:1–13. DOI: 10.1038/s41598-017-15755-1.Sharma N. K., Tashima A. K., Brunialti M. K. C. et al. Proteomic study revealed cellular assembly and lipid metabolism dysregulation in sepsis secondary to community-acquired pneumonia // Sci. Rep. – 2017. – Vol. 7. – P. 1–13. DOI: 10.1038/s41598-017-15755-1.Quevedo-Abeledo J. C., Sánchez-Pérez H., Tejera-Segura B. et al. Differences in HDL-cholesterol efflux capacity between patients with systemic lupus erythematosus and rheumatoid arthritis //Arthritis Care Res. 2021;73(11):1590–1596. DOI: 10.1002/acr.24407.Quevedo-Abeledo J. C., Sánchez-Pérez H., Tejera-Segura B. et al. Differences in HDL-cholesterol efflux capacity between patients with systemic lupus erythematosus and rheumatoid arthritis // Arthritis Care Res. – 2021. – Vol. 73, № 11. – P. 1590–1596. DOI: 10.1002/acr.24407.Hollan I., Meroni P. L., Ahearn J. M. et al. Cardiovascular disease in autoimmune rheumatic diseases // Autoimmun. Rev. 2013;12:1004–1015. DOI: 10.1016/j.autrev.2013.03.013.Hollan I., Meroni P. L., Ahearn J. M. et al. Cardiovascular disease in autoimmune rheumatic diseases // Autoimmun. Rev. – 2013. – Vol. 12. – P. 1004–1015. DOI: 10.1016/j.autrev.2013.03.013.Ferraz-Amaro I., Hernández-Hernández M. V., Armas-González E. et al. HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients // Clin. Rheumatol. 2020;39:1871–1880. DOI: 10.1007/s10067-020- 04961-4.Ferraz-Amaro I., Hernández-Hernández M. V., Armas-González E. et al. HDL cholesterol efflux capacity is related to disease activity in psoriatic arthritis patients // Clin. Rheumatol. – 2020. – Vol. 39. – P. 1871–1880. DOI: 10.1007/s10067-020-04961-4.Sánchez-Pérez H., Quevedo-Abeledo J. C., de Armas-Rillo L. et al. Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis // Rheumatology. 2020;59:2847– 2856. DOI: 10.1093/rheumatology/keaa038.Sánchez-Pérez H., Quevedo-Abeledo J. C., de Armas-Rillo L. et al. Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis // Rheumatology. – 2020. – Vol. 59. – P. 2847–2856. DOI: 10.1093/rheumatology/keaa038.Sánchez-Pérez H., Quevedo-Abeledo J. C., de Armas-Rillo L. et al. Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis // Rheumatology. – 2020. – Vol. 59. – P. 2847–2856. DOI: 10.1093/rheumatology/keaa038.

The authors declare that there are no conflicts of interest present.